Diabetes Drugs Show Promise in Alcohol Use Disorder

Key Takeaways

• Emerging research suggests that diabetes and weight-loss drugs targeting GLP-1 and GIP receptors could help reduce binge drinking and improve liver health.
• Genetic studies provide early evidence that activating these receptors may lower alcohol consumption and protect against alcohol-related complications.
• Semaglutide, a GLP-1 receptor agonist, has shown preliminary results in reducing alcohol cravings, though more large-scale trials are needed.
• These findings highlight the shared biological pathways between appetite regulation and alcohol reward, offering new directions for treatment.
• Current treatments for alcohol use disorder (behavioral therapy, counseling, and approved medications) remain the standard of care.
• GLP-1 and GIP-based medications are not yet approved for treating alcohol use disorder and should only be used under medical supervision in research settings.
• Overall, this research underscores the potential for metabolic therapies to support recovery, while reinforcing the need for ongoing study and comprehensive care.

What’s new

A new analysis in Molecular Psychiatry reports that people who carry genetic variants that mimic the effects of GLP‑1 and GIP receptor activation tend to show less binge drinking and markers consistent with healthier livers. These variants serve as “natural experiments,” letting researchers estimate the long‑term effects of activating these drug targets.

‹›

Why it matters

Alcohol use disorder is common, harmful, and undertreated. Even though approved medications exist, many people do not receive them or do not respond to them. If drugs that modulate GLP1R and GIPR, already used for diabetes and obesity, also reduce harmful drinking, they could expand the treatment toolkit once clinical efficacy is established. For diagnostic definitions and severity levels, see our guide to alcohol use disorder.

How the study worked

Researchers used a drug‑target Mendelian randomization approach. Instead of giving a medicine, they analyzed genetic variants tied to the physiological effects of GLP‑1 and GIP signaling (for example, variants associated with lower HbA1c or lower BMI), then tested links to alcohol behaviors and liver outcomes across large biobanks, including UK Biobank and the Million Veterans Program.

Main findings

• Binge drinking: Genetic proxies for combined GIPR/GLP1R activity were associated with lower binge‑drinking behaviors in primary and replication datasets.
• Heavy drinking with psychiatric comorbidity: Proxies for HbA1c‑lowering via these targets were linked to reduced risk of heavy drinking in people with psychiatric conditions.
• Other substances: No consistent associations were seen for tobacco, cannabis, or opioids.
• Liver health: Signals suggested lower non‑alcoholic fatty liver disease risk and lower ALT levels, consistent with better liver outcomes.
• Diet preference: Variants tied to lower BMI via these targets were associated with lower liking for fatty foods and higher liking for vegetarian foods, hinting at shared biology between appetite regulation and alcohol consumption.

Where clinical data stand now

The genetic evidence aligns with early human studies but does not replace randomized trials.

• A small randomized clinical trial found that once‑weekly semaglutide (a GLP‑1 receptor agonist) reduced alcohol craving and improved some drinking outcomes in adults with AUD, supporting the need for larger, longer trials.
• In a large observational cohort, people prescribed semaglutide had lower incidence and recurrence of AUD compared with those on other anti‑obesity medications over 12 months. Observational designs can’t prove causality but point to a signal worth testing.

Freedom Starts Here. Take Back Your Life Today.

Same-Day Admissions in Austin Available.

Call (512) 605-2955 Verify insurance

What this means for care today

• Promise, not proof: The genetic results suggest that activating GLP‑1 and GIP pathways could reduce harmful drinking and improve related health markers, but clinical trials must confirm benefits, optimal dosing, safety, and who benefits most. Medication is one piece of a broader care plan that includes therapy, skills training, and a personalized relapse prevention plan.
• Mechanistic clues: Appetite and reward pathways may overlap. The same biology that reduces appetite and shifts food preference could also dampen alcohol reward and craving, explaining the patterns seen across genetics and early trials.
• Equity and generalizability: The study included multi‑ancestry analyses; more diverse clinical trials are needed to ensure results apply widely.

If you’re exploring evidence‑based care now, here’s how medication‑assisted treatment (MAT) works at Nova and how it’s combined with therapy.

Limitations to keep in mind

• Genetic proxies ≠ medicines: Mendelian randomization estimates long‑term effects of lifelong genetic differences, not short‑term drug effects. Translation to treatment requires trials.
• Complex behavior: Alcohol use is shaped by biology, psychology, and environment. Pharmacology is one piece of a larger care plan that includes therapy and support.
• Adverse effects and interactions: GLP‑1/GIP‑pathway drugs have known side effects and contraindications that must be weighed in prospective studies.

The bottom line

Growing evidence (from genetics, observational cohorts, and an early randomized trial) suggests that therapies targeting GLP‑1 (and possibly dual GIP/GLP‑1) could help reduce harmful alcohol consumption. These findings justify larger, longer, randomized trials to test efficacy, safety, and patient selection for alcohol use disorder. Until then, any clinical use remains investigational.

How Nova Recovery Center Supports Lasting Recovery from Alcohol Use Disorder

Nova Recovery Center provides comprehensive, evidence-based treatment programs designed to help individuals overcome alcohol use disorder and build a lasting foundation for recovery. Our approach goes beyond detox, addressing the physical, psychological, and emotional aspects of addiction through personalized care plans. Clients have access to a full continuum of services, including inpatient treatment, intensive outpatient programs, sober living options, and long-term support tailored to individual needs. At Nova, evidence-based therapies are combined with holistic practices to heal both mind and body, ensuring each person receives well-rounded care. We also emphasize relapse prevention strategies, peer support, and life skills training to prepare clients for real-world challenges after treatment. With locations in Texas, including Austin and beyond, our center creates a safe and supportive environment for people seeking freedom from alcohol. Our team of experienced professionals is dedicated to guiding clients through every stage of recovery with compassion and expertise. Whether someone is just beginning their recovery journey or needs ongoing support, Nova Recovery Center provides the tools, structure, and encouragement necessary for long-term sobriety.

Other Drug and Alcohol Rehab Locations

• 

  Austin

  Alcohol Detox in Austin, Texas →

• 

  San Antonio

  Drug Detox in San Antonio, Texas →

• 

  Houston

  Drug Detox in Houston, Texas →

Medical Disclaimer

Medical Disclaimer (rewritten for this content):

The information provided on this page is for educational purposes only and should not be taken as medical advice, diagnosis, or treatment. GLP-1 and GIP receptor medications, including semaglutide and tirzepatide, are not approved for the treatment of alcohol use disorder and should only be used under the supervision of a licensed healthcare provider. Do not begin, discontinue, or adjust any medication without consulting your doctor. If you experience severe side effects, worsening symptoms, or thoughts of self-harm, call 911 in the United States or seek immediate medical assistance. For confidential mental health support, dial 988 to reach the Suicide & Crisis Lifeline, available 24 hours a day.

Nova Recovery Center Editorial Guidelines

By instituting a policy, we create a standardized approach to how we create, verify, and distribute all content and resources we produce. An editorial policy helps us ensure that any material our writing and clinical team create, both online and in print, meets or exceeds our standards of integrity and accuracy. Our goal is to demonstrate our commitment to education and patient support by creating valuable resources within our realm of expertise, verifying them for accuracy, and providing relevant, respectful, and insightful data to our clients and families.

References

1. Hendershot, C. S., McClure, E. A., Anton, R. F., Kadden, R. M., Kiefer, F., Leggio, L., … O’Malley, S. S. (2025). Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry. https://jamanetwork.com/journals/jamapsychiatry/ (Accessed October 3, 2025).
2. MedicalXpress. (2025, October 3). Diabetes drugs show promise for treatment of alcohol use disorder. Medical Xpress. https://medicalxpress.com/news/2025-10-diabetes-drugs-treatment-alcohol-disorder.html (Accessed October 3, 2025).
3. Reitz, J., Rosoff, D. B., Sun, J., Clarke, T. K., Polimanti, R., Walters, R. K., … Kranzler, H. R. (2025). Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes. Molecular Psychiatry. https://www.nature.com/articles/s41380-025-03392-0 (Accessed October 3, 2025).
4. Wang, W., Sun, Y., & Ma, J. (2024). Associations of semaglutide with incidence and recurrence of alcohol use disorder. Nature Communications, 15(1). https://www.nature.com/articles/s41467-024-50036-8 (Accessed October 3, 2025).